天宇股份(300702.SZ)：阿帕他胺原料药通过CDE审评

Group 1 - The core point of the article is that Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd., has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation (CDE) for the active pharmaceutical ingredient Apalutamide [1] - Apalutamide is a non-steroidal anti-androgen drug used for the treatment of prostate cancer, functioning by inhibiting the androgen receptor signaling pathway to delay disease progression [1] - The drug is primarily indicated for non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC), and it is to be used in conjunction with castration therapy under medical guidance [1]